Experimental approaches to improve our understanding and treatment of major diabetic complications have focused on single mechanisms or pathways and resulted in the identification of specific mechanisms that drive diabetic damage. With the recent emergence of genome-wide profiling capatiilities and comprehensive data integration strategies, biomedical research is at a point where it can move toward a more holistic view of tissue responses to complex chronic diseases. This is of particular relevance to diabetic end-organ damage since multiple mechanisms converge to slowly alter the cellular milieu in target tissues in diabetes, mandating the integration of separate pathways to elucidate the complex pattern of responses in the treatment or prevention of diabetic complications. Indeed, therapies that have worked best to prevent progression of diabetic nephropathy (DN) and polyneuropathy (DPN) affect multiple pathways and mechanisms, whereas those that target a single, """"""""critical"""""""" pathway have often yielded disappointing results. Our team of scientists will use a systems biology approach to achieve 3 goals, to: 1) efficiently identify the essential cellular responses that lead to DN and DPN, 2) identify those responses that are most amenable to conventional and novel therapies, and 3) discover biomarkers for the critical cellular alterations that lead to complications and respond to effective therapies. Our strategy relies on information-rich sequential and reciprocal transcriptomic, protein and metabolite comparisons between humans with DN and DPN and the best extant murine models of these complications. Our hypothesis is that a complex network of responses, including but not limited to those altered by oxidant stress, leads to the onset and progression of diabetic microvascular complications. These critical responses will be identified by performing genome-wide RNA and metabolite profiles from kidney and nerve of humans with DN and DPN. The expression data sets of human end-organ damage from untreated and treated animals will be compared to data sets obtained from kidney and nerve from murine models with DN and DPN. Three different treatment paradigms known to ameliorate DN and DPN will be used as independent tools in the mouse models to identify new critical responses that lead to complications and are responsible for effective treatment in humans. This reciprocal cross-species approach will identify candidate pathways and molecules whose regulation alters disease progression. Finally, we will return to the murine models of DN and DPN to discover new biomarkers that will be useful in the diagnosis and therapeutic management of human DN and DPN.
Two of the most devastating complications of diabetes are kidney disease and nerve disease which both result in increased illness and death. The multifactorial causes of these complications remain poorly understood and treatments are limited. Therefore, we have devised a team approach to use systems biology to study diabetic humans with these complications, with the help of mouse models, and to identify the critical molecular responses that cause kidney and nerve damage and that can be reversed by therapy.
|Callaghan, Brian C; Xia, Rong; Reynolds, Evan et al. (2018) Better diagnostic accuracy of neuropathy in obesity: A new challenge for neurologists. Clin Neurophysiol 129:654-662|
|Rumora, Amy E; Lentz, Stephen I; Hinder, Lucy M et al. (2018) Dyslipidemia impairs mitochondrial trafficking and function in sensory neurons. FASEB J 32:195-207|
|Simó, Rafael; Stitt, Alan W; Gardner, Thomas W (2018) Neurodegeneration in diabetic retinopathy: does it really matter? Diabetologia 61:1902-1912|
|Sas, Kelli M; Lin, Jiahe; Rajendiran, Thekkelnaycke M et al. (2018) Shared and distinct lipid-lipid interactions in plasma and affected tissues in a diabetic mouse model. J Lipid Res 59:173-183|
|Jadoon, Adil; Mathew, Anna V; Byun, Jaeman et al. (2018) Gut Microbial Product Predicts Cardiovascular Risk in Chronic Kidney Disease Patients. Am J Nephrol 48:269-277|
|Wernisch, Stefanie; Afshinnia, Farsad; Rajendiran, Thekkelnaycke et al. (2018) Probing the application range and selectivity of a differential mobility spectrometry-mass spectrometry platform for metabolomics. Anal Bioanal Chem 410:2865-2877|
|Nair, Viji; Komorowsky, Claudiu V; Weil, E Jennifer et al. (2018) A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome. Kidney Int 93:439-449|
|Afshinnia, Farsad; Rajendiran, Thekkelnaycke M; Soni, Tanu et al. (2018) Impaired ?-Oxidation and Altered Complex Lipid Fatty Acid Partitioning with Advancing CKD. J Am Soc Nephrol 29:295-306|
|Hinder, Lucy M; Murdock, Benjamin J; Park, Meeyoung et al. (2018) Transcriptional networks of progressive diabetic peripheral neuropathy in the db/db mouse model of type 2 diabetes: An inflammatory story. Exp Neurol 305:33-43|
|Brosius, Frank C; Ju, Wenjun (2018) The Promise of Systems Biology for Diabetic Kidney Disease. Adv Chronic Kidney Dis 25:202-213|
Showing the most recent 10 out of 93 publications